Junshi Biosciences Announces Acceptance of the Supplemental Application for Toripalimab plus Chemotherapy as Perioperative Treatment for Resectable Stage Ⅱ-Ⅲ NSCLC

Junshi Biosciences Announces Acceptance of the Supplemental Application for Toripalimab plus Chemotherapy as Perioperative Treatment for Resectable Stage Ⅱ-Ⅲ NSCLC

Notified -...

Junshi Biosciences Announces Primary Endpoints Met in Final Analysis of Phase 3 Study for Perioperative Toripalimab plus Chemotherapy for Resectable Stage II-III NSCLC

Junshi Biosciences Announces Primary Endpoints Met in Final Analysis of Phase 3 Study for Perioperative Toripalimab plus Chemotherapy for Resectable Stage II-III NSCLC

Notified -...

Junshi Biosciences Announces Approval of Toripalimab NDA for the 1st-line treatment of HER2 Expressing Urothelial Carcinoma

Junshi Biosciences Announces Approval of Toripalimab NDA for the 1st-line treatment of HER2 Expressing Urothelial Carcinoma

Notified -...

Toripalimab Presents Long-Term Survival Benefits as 1st-line Treatment for Advanced Nasopharyngeal Carcinoma and Esophageal Squamous Cell Carcinoma Patients

Toripalimab Presents Long-Term Survival Benefits as 1st-line Treatment for Advanced Nasopharyngeal Carcinoma and Esophageal Squamous Cell Carcinoma Patients

Notified -...

Junshi Biosciences Announces Primary Endpoints Met in JS001sc’s Phase 3 Study for the 1ST-line Treatment of NSQ-NSCLC

Junshi Biosciences Announces Primary Endpoints Met in JS001sc’s Phase 3 Study for the 1ST-line Treatment of NSQ-NSCLC

Notified -...

Junshi Biosciences Announces the sNDA Approval of Toripalimab for the 1st-line Treatment of Melanoma

Junshi Biosciences Announces the sNDA Approval of Toripalimab for the 1st-line Treatment of Melanoma

Notified -...

Junshi Biosciences Announces Toripalimab’s Approval in Singapore

Junshi Biosciences Announces Toripalimab’s Approval in Singapore

Notified -...

menu
menu